In male Charles Foster rats in an NIDDM model, Swertiamarin at 50 mg/kg/day p.o. for 40 days reduced serum triglycerides near to control levels compared with DM, reaching 63.34 ± 7.86 mg/dL. Under the same treatment conditions, total cholesterol was 86.75 ± 13.64 mg/dL, with DM as the comparator. In male C57BL/6 mice fed HFD, dietary Swertiamarin at 0.01% (w/w) or 0.1% (w/w) for 8 weeks yielded plasma total cholesterol levels of 93.2 ± 5.7 mg/dL and 68.3 ± 10.4 mg/dL, respectively, compared with 105.4 ± 10.2 mg/dL in the HFD control. In male Wistar rats without CS treatment, oral Swertiamarin at 32 mg/kg/d for 90 days did not increase or decrease Hyp content relative to vehicle control. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Serum Triglycerides in NIDDM Rats
Animal study · Male Charles Foster rats; NIDDM rat model; six rats in each group [1]
Male Charles Foster rats in an NIDDM model received Swertiamarin at 50 mg/kg/day p.o. for 40 days. Compared with DM, serum triglycerides were reduced near to control levels, reaching 63.34 ± 7.86 mg/dL.
Conditions shared by the study groups
- Route
- p.o.
- Treatment course
- 40 days
- Swertiamarin 50 mg/kg/day
- Model: Male Charles Foster rats; NIDDM rat model; six rats in each group
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Swertiamarin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.2. Animals and Housing (S15, S17); 2. Materials and Methods > 2.3. Dosing of Swertiamarin and Aqueous Extract in NIDDM Rats (S19, S20); 3. Results > 3.6. Lipid Profile (S83); Table 2 legend (S133); Table 2 (T2.h1, T2.r1)
serum triglyceride levels: serum triglyceride levels; comparator: DM — 2. Materials and Methods > 2.3. Dosing of Swertiamarin and Aqueous Extract in NIDDM Rats (S19); 3. Results > 3.6. Lipid Profile (S83); Table 2 legend (S133); Table 2 (T2.h1, T2.r1)
Swertiamarin 50 mg/kg/day · 2. Materials and Methods > 2.3. Dosing of Swertiamarin and Aqueous Extract in NIDDM Rats (S19, S20); 3. Results > 3.6. Lipid Profile (S83); Table 2 legend (S133); Table 2 (T2.h1, T2.r1)
Plasma total cholesterol in mice fed HFD
Animal study · Eight-week-old male C57BL/6 mice; HFD (n = 6) [2]
Male C57BL/6 mice fed HFD received dietary Swertiamarin at 0.01% (w/w) or 0.1% (w/w) for 8 weeks. Plasma total cholesterol was 93.2 ± 5.7 mg/dL and 68.3 ± 10.4 mg/dL, respectively, compared with 105.4 ± 10.2 mg/dL in the HFD control.
Conditions shared by the study groups
- Route
- fed
- Treatment course
- 8 weeks
- Swertiamarin 0.01% (w/w); 0.1% (w/w)
- Model: Eight-week-old male C57BL/6 mice; HFD (n = 6)
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Swertiamarin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Animals and diets (S1); Results > Swertiamarin reduces body weight and alleviates insulin resistance in mice fed a HFD (S53); Figure 1. legend (S158); Figure 2. legend (S159); Table 1. legend (S207, S209); Table 1. (T1.h1, T1.r3)
Plasma TC(mg/dL): Plasma TC(mg/dL); comparator: HFD — Table 1. legend (S207, S209); Table 1. (T1.h1, T1.r3)
Swertiamarin 0.01% (w/w); 0.1% (w/w) · Materials and Methods > Animals and diets (S1); Table 1. legend (S207, S209); Table 1. (T1.h1, T1.r3)
Hyp Content in Rats Without CS Treatment
Animal study · Male Wistar rats; another 6 rats; without CS treatment [3]
Male Wistar rats without CS treatment received Swertiamarin orally at 32 mg/kg/d for 90 days. Hyp content did not increase or decrease compared with vehicle control.
Conditions shared by the study groups
- Route
- orally
- Treatment course
- for 90 days
- Swertiamarin 32 mg/kg/d
- Model: Male Wistar rats; another 6 rats; without CS treatment
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Swertiamarin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Swertiamarin ameliorated CS-induced prostatic collagen deposition (S8); MATERIALS AND METHODS > Rat model of CS exposure (S42, S51)
Hyp content: Hyp content; comparator: vehicle control — RESULTS > Swertiamarin ameliorated CS-induced prostatic collagen deposition (S8)
Swertiamarin 32 mg/kg/d · RESULTS > Swertiamarin ameliorated CS-induced prostatic collagen deposition (S8); MATERIALS AND METHODS > Rat model of CS exposure (S51)
Total Cholesterol in NIDDM Rats
Animal study · Male Charles Foster rats; NIDDM rat model; six rats in each group [1]
Male Charles Foster rats in an NIDDM model received Swertiamarin at 50 mg/kg/day p.o. for 40 days. In the comparison with DM, total cholesterol was reported as 86.75 ± 13.64 mg/dL.
Conditions shared by the study groups
- Route
- p.o.
- Treatment course
- 40 days
- Swertiamarin 50 mg/kg/day
- Model: Male Charles Foster rats; NIDDM rat model; six rats in each group
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Swertiamarin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.2. Animals and Housing (S15, S17); 2. Materials and Methods > 2.3. Dosing of Swertiamarin and Aqueous Extract in NIDDM Rats (S19, S20); Table 2 legend (S133); Table 2 (T2.h1, T2.r2)
Total cholesterol: Total cholesterol; comparator: DM — Table 2 legend (S133); Table 2 (T2.h1, T2.r2)
Swertiamarin 50 mg/kg/day · 2. Materials and Methods > 2.3. Dosing of Swertiamarin and Aqueous Extract in NIDDM Rats (S19, S20); Table 2 legend (S133); Table 2 (T2.h1, T2.r2)